Objectives-Hyperphosphatasaemia has
y-glutamyltranspeptidase (GTP), leucine aminopeptidase (LAP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT)), immunoglobulins, RA haemagglutinin test (RAHA), C reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were observed in 288 patients with rheumatoid arthritis. Results-Serum biliary ALP (ALP1) activity was detected in 31.6% of the patients. In patients positive for ALP1 the respective values of total ALP (ALPt) (p<0001), liver ALP (ALP2) (p<0-001), bone ALP (ALP3) (p<005), y-GTP (p<OOOl), LAP (p<0001), immunoglobulins IgG (p<001), IgA (p<001), and IgM (p<001), RAHA (p<0001), CRP (p<0001), ESR (p<0001), and articular index (p<0001) were significantly higher than in patients who did not have ALP1. Significant Spearman's rank correlations (rs) were demonstrated between serum ALP2 level and the respective values of ALPt (rs=09128, p<0-001), ALP, (rs= 04443, p<0.001), ALP3 (rs=05898, p<0001), y-GTP (rs=02903, p<0001), LAP (rs=03093, p<0001), IgA (rs=022995 p<0-01), IgM (rs=017735 p<005), RAHA (rs=02420, p<001), CRP (rs=0.35325 p<0001), ESR (rs=0.4108, p<0001), and the articular index (rs=040065 p<0-001).
However, no significant difference or correlation was noted for either AST or ALT. In many patients who showed abnormal hyperphosphatasaemia, hepatobiliary enzyme dissociation was observed: levels ofALPt (in 12-8%), ALP1 (in 31.6%)/ ALP2 (18.8%)/ -y-GTP (in 4.3%), and LAP (in 19 .3%) were abnormally high, but both AST and ALT were within normal limits. Conclusion-These findings are considered to be characteristic of RA, and suggest the existence of latent or subclinical hepatobiliary involvement and an association between the expansion of hepatobiliary involvement and the mechanism of disease activation. Thus measurement of the serum levels of ALP and its isoenzymes in RA is considered to be important. The level of serum alkaline phosphatase (ALP) in patients with rheumatoid arthritis (RA) is thought to be within normal limits. Hyperphosphatasaemia has been observed occasionally in patients with RA, however, despite the absence of any clinical hepatobiliary disorder.' 1-2 Comparison between patients with RA and osteoarthritis has shown a higher serum ALP level in RA.3 10 12 These reports suggest an increase of the baseline serum ALP level in RA, although the underlying mechanism remains uncertain. Most reports have described that the raised serum ALP activity originates in the liver or bone, or both, from observations of ALP isoenzymes.i" Rosalki, Foo, and Tanner" reported detection of serum biliary ALP isoenzyme (ALP1) activity, which is macromolecular and is thought to be detectable only in cholestasis. '3-15 Recently, observation of serum samples from patients with RA suggested that ALP1 activity was detectable at a high prevalence of about 30%./12 Furthermore, this report suggested that serum levels of liver ALP (ALP2) and bone ALP (ALP3) isoenzymes, as well as total ALP (ALPt) in patients with RA, were higher than in those with osteoarthritis, and that these levels in patients with RA who were ALP1 positive were higher than those who were negative. No ALP1 activity was detectable in serum samples from patients with osteoarthritis. Based on these findings, serum hepatobiliary enzyme activities in RA were observed in the present study. It is suggested that the serum ALP level is related to RA disease activity.1-3 [5] [6] [7] [8] [9] [10] [11] [12] The relation between serum ALP and RA disease activity was also studied, therefore, based on observations of immunoglobulins, C reactive protein (CRP), erythrocyte sedimentation rate (ESR), and articular index. ' to be produced by the activated bone formation: this is to say, a rise of ALP3 is not a cause but a result of disease activation. Therefore, a significant correlation between ALP2 and ALP3 was considered to be present (fig 1) . In four patients negative for ALP, showing abnormal hyperphosphatasaemia, however, the ALP3 level was considerably raised (patients 1-4 in table 1). From these facts, the existence of other disease activation mechanisms, which are not associated with hepatobiliary enzyme dissociation, is also suggested. In actual cases, both mechanisms would work concurrently. Whichever mechanism operates, serum ALPt activity may have to increase in parallel with disease activity in RA. In fact, three of these four patients also had a high ALP2 level (table 1) . Therefore, ALP,, ALP2, and ALP3 are considered important for the evaluation of disease activation. To determine whether the disease activity is associated with ALP activities, however, other markers that directly indicate the disease activity should be monitored in the long term.
There is also a possibility that rises in ALP, y-GTP, and LAP are due to liver toxicity resulting from treatment with non-steroidal anti-inflammatory drugs, disease modifying antirheumatic drugs, or corticosteroids. In the present study, however, no pathological increase of AST and ALT was observed in any subject even though treatment with these drugs was continued. The previous study"2 also showed that this was unlikely, as ALP isoenzyme activities did not differ among patients treated with these drugs. Doube et al30 also reported that non-steroidal antiinflammatory drugs had no influence on ALP activity in patients with RA. Therefore, rises in these enzymes are considered to be attributable to RA itself.
Webb et al,' Spooner et al,8 and Kantharia
and Woolf'3 demonstrated cases of RA and primary biliary cirrhosis overlapping. In the present study, however, patients with apparent hepatobiliary disorders, such as cirrhosis or hepatitis, were excluded and both AST and ALT were at normal levels. Thus the present findings indicate that serum biliary enzymes, expecially ALPt, ALP,, and ALP2, are related closely to the activity of RA and subclinical hepatobiliary involvement by RA, which is observed in the latent and subclinical stages as hepatobiliary enzme dissociation.
